[{"id":"2487ddb2-7738-4021-b64c-94036379e85b","acronym":"CHAMP","url":"https://clinicaltrials.gov/study/NCT04709276","created_at":"2021-01-19T20:52:08.240Z","updated_at":"2025-02-25T14:29:51.192Z","phase":"Phase 2","brief_title":"A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04709276 - CHAMP","lead_sponsor":"Andrew J. Armstrong, MD","biomarkers":" TP53 • PTEN • RB1 • SYP","pipe":" | ","alterations":" LDH elevation","tags":["TP53 • PTEN • RB1 • SYP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/07/2021","start_date":" 06/07/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 06/01/2028","study_completion_date":" 06/01/2028","last_update_posted":"2025-02-14"},{"id":"21e02173-6a70-45fc-8771-2545b671be82","acronym":"NCI-2018-01071","url":"https://clinicaltrials.gov/study/NCT03263650","created_at":"2021-01-18T16:07:22.101Z","updated_at":"2025-02-25T14:58:18.982Z","phase":"Phase 2","brief_title":"Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men with AVPC","source_id_and_acronym":"NCT03263650 - NCI-2018-01071","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1 • CEACAM5","pipe":"","alterations":" ","tags":["TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 10/03/2017","start_date":" 10/03/2017","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-05"},{"id":"e9087e98-84d9-4794-8123-a03a7c489eac","acronym":"CHAARTED2","url":"https://clinicaltrials.gov/study/NCT03419234","created_at":"2025-02-25T17:35:55.932Z","updated_at":"2025-02-25T17:35:55.932Z","phase":"Phase 2","brief_title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","source_id_and_acronym":"NCT03419234 - CHAARTED2","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 04/26/2018","start_date":" 04/26/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-29"},{"id":"8247cdb4-7bc6-434e-8424-d805cacb6db9","acronym":"LuCAB","url":"https://clinicaltrials.gov/study/NCT05340374","created_at":"2022-04-22T14:53:47.311Z","updated_at":"2025-02-25T17:37:46.899Z","phase":"Phase 1/2","brief_title":"Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer","source_id_and_acronym":"NCT05340374 - LuCAB","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 07/14/2022","start_date":" 07/14/2022","primary_txt":" Primary completion: 06/20/2026","primary_completion_date":" 06/20/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-11-08"},{"id":"b733a5ee-f14d-459f-a343-1204a150af38","acronym":"PEAPOD_FOS","url":"https://clinicaltrials.gov/study/NCT05563558","created_at":"2022-10-03T15:56:36.500Z","updated_at":"2024-07-02T16:34:27.128Z","phase":"Phase 2","brief_title":"Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)","source_id_and_acronym":"NCT05563558 - PEAPOD_FOS","lead_sponsor":"Fundacion Oncosur","biomarkers":" TP53 • PTEN • CEACAM5","pipe":"","alterations":" ","tags":["TP53 • PTEN • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • carboplatin • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 05/05/2023","start_date":" 05/05/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-06-11"},{"id":"ccfd455c-e774-4e0e-bb52-ee525cf236c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT04592237","created_at":"2021-01-19T20:28:42.436Z","updated_at":"2024-07-02T16:34:58.883Z","phase":"Phase 2","brief_title":"Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer","source_id_and_acronym":"NCT04592237","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1 • TP53 • PTEN • RB1 • CEACAM5","pipe":" | ","alterations":" PTEN mutation","tags":["PD-L1 • TP53 • PTEN • RB1 • CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 12/29/2020","start_date":" 12/29/2020","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-06-04"},{"id":"d79bfdb8-ad5a-46da-91a6-a2f9ca67b203","acronym":"DynaMO","url":"https://clinicaltrials.gov/study/NCT02703623","created_at":"2021-01-18T13:12:02.865Z","updated_at":"2024-07-02T16:35:03.313Z","phase":"Phase 2","brief_title":"Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT02703623 - DynaMO","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • apalutamide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 196","initiation":"Initiation: 05/18/2016","start_date":" 05/18/2016","primary_txt":" Primary completion: 03/31/2026","primary_completion_date":" 03/31/2026","study_txt":" Completion: 03/31/2026","study_completion_date":" 03/31/2026","last_update_posted":"2024-05-16"},{"id":"8b035599-60c6-4e12-a848-25b7b29e695c","acronym":"","url":"https://clinicaltrials.gov/study/NCT05005728","created_at":"2021-08-13T12:53:42.693Z","updated_at":"2024-07-02T16:35:16.340Z","phase":"Phase 2","brief_title":"XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT05005728","lead_sponsor":"Xencor, Inc.","biomarkers":" TMB • MSI • HRD","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI • HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-03-05"},{"id":"366da270-8f09-44d6-be12-90adac16a8b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06085729","created_at":"2023-10-17T15:12:33.301Z","updated_at":"2024-07-02T16:35:16.807Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)","source_id_and_acronym":"NCT06085729","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TP53 • PTEN • RB1","pipe":" | ","alterations":" TP53 mutation • PTEN mutation • LDH elevation","tags":["TP53 • PTEN • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • PTEN mutation • LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Rybrevant (amivantamab-vmjw) • Tepmetko (tepotinib) • cabazitaxel • Hepacid (pegargiminase)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-01"},{"id":"9afa8d89-1ac9-4a2d-81e2-452735aa78c1","acronym":"CABA-V7","url":"https://clinicaltrials.gov/study/NCT03050866","created_at":"2021-08-20T20:55:35.989Z","updated_at":"2024-07-02T16:36:26.076Z","phase":"Phase 2","brief_title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","source_id_and_acronym":"NCT03050866 - CABA-V7","lead_sponsor":"Erasmus Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR-V7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 140","initiation":"Initiation: 02/21/2017","start_date":" 02/21/2017","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 08/19/2022","study_completion_date":" 08/19/2022","last_update_posted":"2021-08-20"},{"id":"4a8d88e3-ddfb-402c-8c7f-3570d00d5e4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01505868","created_at":"2021-01-18T06:19:34.369Z","updated_at":"2024-07-02T16:36:27.231Z","phase":"Phase 1/2","brief_title":"Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT01505868","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CEACAM5","pipe":"","alterations":" ","tags":["CEACAM5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 170","initiation":"Initiation: 07/11/2012","start_date":" 07/11/2012","primary_txt":" Primary completion: 12/09/2019","primary_completion_date":" 12/09/2019","study_txt":" Completion: 12/09/2019","study_completion_date":" 12/09/2019","last_update_posted":"2021-07-30"},{"id":"91f25517-3648-4010-96ee-c139f5875d49","acronym":"CABA-BONE","url":"https://clinicaltrials.gov/study/NCT02512458","created_at":"2021-01-18T12:08:14.634Z","updated_at":"2024-07-02T16:36:50.251Z","phase":"Phase 2","brief_title":"Study of the Effect of Chemotherapy With Cabazitaxel on Prostate Cancer","source_id_and_acronym":"NCT02512458 - CABA-BONE","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" TP53 • AR • CYP17A1 • NKX3-1 • UBE2C","pipe":" | ","alterations":" AR expression • TP53 expression","tags":["TP53 • AR • CYP17A1 • NKX3-1 • UBE2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • TP53 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"Initiation: 10/29/2015","start_date":" 10/29/2015","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 12/27/2019","study_completion_date":" 12/27/2019","last_update_posted":"2020-02-10"},{"id":"e4b470a6-e3f3-473a-b3dd-c583115f597e","acronym":"PROSTAC","url":"https://clinicaltrials.gov/study/NCT02362620","created_at":"2021-01-18T11:14:49.607Z","updated_at":"2024-07-02T16:36:50.915Z","phase":"","brief_title":"PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel.","source_id_and_acronym":"NCT02362620 - PROSTAC","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • ERG • TMPRSS2","pipe":" | ","alterations":" PTEN loss","tags":["PTEN • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN loss"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 402","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"3fb805a1-f279-46f9-8c23-0046d72d1001","acronym":"","url":"https://clinicaltrials.gov/study/NCT03048942","created_at":"2021-01-18T15:00:53.455Z","updated_at":"2024-07-02T16:36:53.747Z","phase":"Phase 2","brief_title":"Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer","source_id_and_acronym":"NCT03048942","lead_sponsor":"University Hospitals Bristol and Weston NHS Foundation Trust","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cabazitaxel"],"overall_status":"Recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 11/01/2014","start_date":" 11/01/2014","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2019-11-13"},{"id":"767c3252-70b0-43a5-8f16-55162b11e9d9","acronym":"CABACARE","url":"https://clinicaltrials.gov/study/NCT03356912","created_at":"2021-01-18T16:34:15.578Z","updated_at":"2024-07-02T16:37:15.509Z","phase":"Phase 2","brief_title":"CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy","source_id_and_acronym":"NCT03356912 - CABACARE","lead_sponsor":"Consorzio Oncotech","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 11/22/2017","start_date":" 11/22/2017","primary_txt":" Primary completion: 05/04/2021","primary_completion_date":" 05/04/2021","study_txt":" Completion: 05/04/2021","study_completion_date":" 05/04/2021","last_update_posted":"2017-12-14"},{"id":"97993249-9b0e-4d8d-becd-cd4dbf8ec23d","acronym":"TAXYNERGY","url":"https://clinicaltrials.gov/study/NCT01718353","created_at":"2021-01-18T07:29:43.577Z","updated_at":"2024-07-02T16:37:16.210Z","phase":"Phase 2","brief_title":"Early Switch From First-Line Docetaxel/Prednisone to Cabazitaxel/Prednisone and the Opposite Sequence, Exploring Molecular Markers in Men With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","source_id_and_acronym":"NCT01718353 - TAXYNERGY","lead_sponsor":"Sanofi","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • prednisone • cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 63","initiation":"Initiation: 03/01/2013","start_date":" 03/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2017-11-20"},{"id":"7f2dfcd6-333e-4f40-bb13-af5d28d5f4cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT01693549","created_at":"2021-01-18T07:21:21.525Z","updated_at":"2024-07-02T16:37:19.291Z","phase":"Phase 2","brief_title":"Study of Cabazitaxel in Patients With Metastatic Breast Cancer Previously Treated With Taxanes","source_id_and_acronym":"NCT01693549","lead_sponsor":"Hellenic Cooperative Oncology Group","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 09/01/2012","start_date":" 09/01/2012","primary_txt":" Primary completion: 07/10/2017","primary_completion_date":" 07/10/2017","study_txt":" Completion: 07/20/2017","study_completion_date":" 07/20/2017","last_update_posted":"2017-08-01"},{"id":"7fb965ba-5760-40c4-b2b8-3b9803684fbc","acronym":"GENEVIEVE","url":"https://clinicaltrials.gov/study/NCT01779479","created_at":"2021-01-18T07:51:50.642Z","updated_at":"2024-07-02T16:37:19.252Z","phase":"Phase 2","brief_title":"Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)","source_id_and_acronym":"NCT01779479 - GENEVIEVE","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cabazitaxel"],"overall_status":"Completed","enrollment":" Enrollment 333","initiation":"Initiation: 02/01/2013","start_date":" 02/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 02/01/2016","study_completion_date":" 02/01/2016","last_update_posted":"2017-08-01"},{"id":"4a5ef320-f912-4490-8737-c7482457db3c","acronym":"CARVE","url":"https://clinicaltrials.gov/study/NCT02621190","created_at":"2021-07-07T15:53:53.162Z","updated_at":"2024-07-02T16:37:29.724Z","phase":"Phase 2","brief_title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs","source_id_and_acronym":"NCT02621190 - CARVE","lead_sponsor":"Erasmus Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7 • AR-V7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7 • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • cabazitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2016-08-17"},{"id":"5d6cbcc7-bf12-4491-b7b8-a8eecb1bd568","acronym":"SensiCab","url":"https://clinicaltrials.gov/study/NCT01978873","created_at":"2021-01-18T09:00:46.031Z","updated_at":"2024-07-02T16:37:32.413Z","phase":"Phase 3","brief_title":"Efficacy Study Evaluating Chemotherapy in Prostate Cancer","source_id_and_acronym":"NCT01978873 - SensiCab","lead_sponsor":"Örebro University, Sweden","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 400","initiation":"Initiation: 11/01/2012","start_date":" 11/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2019","study_completion_date":" 11/01/2019","last_update_posted":"2016-05-04"}]